Cargando…

DNA damage response as a prognostic indicator in metastatic breast cancer via mutational analysis

BACKGROUND: High tumor heterogeneity contributes to breast cancer recurrence and metastasis. However, the lack of indicators to serve as precise and reliable means of predicting breast cancer prognosis has yet to be addressed. This study aims to reveal the prognostic relevance of mutations in metast...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rong, Guohua, Yi, Zongbi, Ma, Fei, Guan, Yanfang, Xu, Yaping, Li, Lifeng, Xu, Binghe
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7940884/ https://www.ncbi.nlm.nih.gov/pubmed/33708847 http://dx.doi.org/10.21037/atm-20-2137

Ejemplares similares

Mutational characteristics determined using circulating tumor DNA analysis in triple‐negative breast cancer patients with distant metastasis
por: Rong, Guohua, et al.
Publicado: (2020)

Clinical spectrum and prognostic value of TP53 mutations in circulating tumor DNA from breast cancer patients in China
por: Yi, Zongbi, et al.
Publicado: (2020)

ctDNA dynamics: a novel indicator to track resistance in metastatic breast cancer treated with anti-HER2 therapy
por: Ma, Fei, et al.
Publicado: (2016)

Molecular landscape and efficacy of HER2-targeted therapy in patients with HER2-mutated metastatic breast cancer
por: Yi, Zongbi, et al.
Publicado: (2020)

Landscape of somatic mutations in different subtypes of advanced breast cancer with circulating tumor DNA analysis
por: Yi, Zongbi, et al.
Publicado: (2017)

Everolimus in hormone receptor-positive metastatic breast cancer: PIK3CA mutation H1047R was a potential efficacy biomarker in a retrospective study
por: Yi, Zongbi, et al.
Publicado: (2019)

Genome-wide chromosomal instability by cell-free DNA sequencing predicts survival in patients with metastatic breast cancer
por: Mo, Hongnan, et al.
Publicado: (2020)

The molecular tumor burden index as a response evaluation criterion in breast cancer
por: Yi, Zongbi, et al.
Publicado: (2021)

Epithelial-Mesenchymal-Transition-Like Circulating Tumor Cell-Associated White Blood Cell Clusters as a Prognostic Biomarker in HR-Positive/HER2-Negative Metastatic Breast Cancer
por: Guan, Xiuwen, et al.
Publicado: (2021)

Molecular landscape of TP53 mutations in breast cancer and their utility for predicting the response to HER‐targeted therapy in HER2 amplification‐positive and HER2 mutation‐positive amplification‐negative patients
por: Liu, Binliang, et al.
Publicado: (2022)

Gut Microbiota Profiling in Patients With HER2-Negative Metastatic Breast Cancer Receiving Metronomic Chemotherapy of Capecitabine Compared to Those Under Conventional Dosage
por: Guan, Xiuwen, et al.
Publicado: (2020)

The Efficacy and Safety of Programmed Cell Death 1 and Programmed Cell Death 1 Ligand Inhibitors for Advanced Melanoma: A Meta-Analysis of Clinical Trials Following the PRISMA Guidelines
por: Guan, Xiuwen, et al.
Publicado: (2016)

Safety and efficacy of sirolimus combined with endocrine therapy in patients with advanced hormone receptor-positive breast cancer and the exploration of biomarkers
por: Yi, Zongbi, et al.
Publicado: (2020)

Analysis of the hormone receptor status of circulating tumor cell subpopulations based on epithelial-mesenchymal transition: a proof-of-principle study on the heterogeneity of circulating tumor cells
por: Guan, Xiuwen, et al.
Publicado: (2016)

The association between early-onset cardiac events caused by neoadjuvant or adjuvant chemotherapy in triple-negative breast cancer patients and some novel autophagy-related polymorphisms in their genomic DNA: a real-world study
por: Liu, Binliang, et al.
Publicado: (2018)

DNA damage repair mutations in pancreatic cancer– prognostic or predictive?
por: Hu, Ya-Fei, et al.
Publicado: (2023)

Plasma cell-free DNA and survival in non-small-cell lung cancer: A meta-analysis
por: Yi, Zongbi, et al.
Publicado: (2017)

Longitudinal HER2 amplification tracked in circulating tumor DNA for therapeutic effect monitoring and prognostic evaluation in patients with breast cancer
por: Guan, Xiuwen, et al.
Publicado: (2019)

Prognostic analysis of patients with breast cancer based on tumor mutational burden and DNA damage repair genes
por: Teng, Xu, et al.
Publicado: (2023)

Dynamics of circulating microRNAs as a novel indicator of clinical response to neoadjuvant chemotherapy in breast cancer
por: Zhu, Wenjie, et al.
Publicado: (2018)

Prognostic Role of DNA Damage Response Genes Mutations and their Association With the Sensitivity of Olaparib in Prostate Cancer Patients
por: Zhang, Dong, et al.
Publicado: (2022)

Pyrotinib plus capecitabine could significantly improve overall survival in HER2-positive metastatic breast cancer
por: Guan, Xiuwen, et al.
Publicado: (2023)

Clinical factors associated with circulating tumor DNA (ctDNA) in primary breast cancer
por: Zhou, Yidong, et al.
Publicado: (2019)

Biomarkers of Everolimus Sensitivity in Hormone Receptor-Positive Breast Cancer
por: Yi, Zongbi, et al.
Publicado: (2017)

Prognostic Factors and a Model for Occult Breast Cancer: A Population-Based Cohort Study
por: Zhang, Di, et al.
Publicado: (2022)

Multi-omics fusion analysis models with machine learning predict survival of HER2-negative metastatic breast cancer: a multicenter prospective observational study
por: Wang, Jiani, et al.
Publicado: (2023)

Clinicopathological characteristics and survival outcomes in patients with synchronous lung metastases upon initial metastatic breast cancer diagnosis in Han population
por: Lin, Shaoyan, et al.
Publicado: (2021)

Pan-cancer circulating tumor DNA detection in over 10,000 Chinese patients
por: Zhang, Yongliang, et al.
Publicado: (2021)

The prognostic and therapeutic implications of circulating tumor cell phenotype detection based on epithelial–mesenchymal transition markers in the first-line chemotherapy of HER2-negative metastatic breast cancer
por: Guan, Xiuwen, et al.
Publicado: (2019)

Mutated DNA Damage Repair Pathways Are Prognostic and Chemosensitivity Markers for Resected Colorectal Cancer Liver Metastases
por: Wang, Kun, et al.
Publicado: (2021)

Author Correction: Pan-cancer circulating tumor DNA detection in over 10,000 Chinese patients
por: Zhang, Yongliang, et al.
Publicado: (2021)

PIM1 and CD79B Mutation Status Impacts the Outcome of Primary Diffuse Large B-Cell Lymphoma of the CNS
por: Zhou, Jihao, et al.
Publicado: (2022)

Efficacy and Safety of Bevacizumab in Pretreated Metastatic Breast Cancer: A Systematic Review and Meta-Analysis
por: Li, Zhijun, et al.
Publicado: (2022)

Prognostic Factors for Triple-Negative Breast Cancer with Residual Disease after Neoadjuvant Chemotherapy
por: Li, Zhijun, et al.
Publicado: (2023)

The use of DNA repair genes as prognostic indicators of gastric cancer
por: Jinjia, Chang, et al.
Publicado: (2019)

Identification of prognostic factors and surgical indications for metastatic gastric cancer
por: Mohri, Yasuhiko, et al.
Publicado: (2014)

Polymorphisms of MTHFR and TYMS predict capecitabine-induced hand-foot syndrome in patients with metastatic breast cancer
por: Lin, Shaoyan, et al.
Publicado: (2019)

Retrospective literature review of primary neuroendocrine neoplasms of the breast (BNEN) in 209 Chinese patients: Treatment and prognostic factor analysis
por: Chai, Yue, et al.
Publicado: (2022)

A Novel Prognostic Nomogram for Predicting Survival of Hormone Receptor-Positive and HER2 Negative Advanced Breast Cancer Among the Han-Population
por: Zhu, Yimin, et al.
Publicado: (2022)

Prognostic Value of the TP53 Mutation Location in Metastatic Breast Cancer as Detected by Next-Generation Sequencing
por: Bai, Han, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_1roihe6e40ri6ad8b65sgl5pg6